Aadi Liabilities And Stockholders Equity from 2010 to 2024

AADI Stock  USD 2.31  0.09  4.05%   
Aadi Bioscience's Liabilities And Stockholders Equity is increasing with slightly volatile movements from year to year. Liabilities And Stockholders Equity is estimated to finish at about 139 M this year. Liabilities And Stockholders Equity is the total of all liabilities and equity in the company, which should equal Aadi Bioscience's total assets according to the accounting equation. View All Fundamentals
 
Liabilities And Stockholders Equity  
First Reported
2008-03-31
Previous Quarter
101.6 M
Current Value
85.7 M
Quarterly Volatility
57.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aadi Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aadi Bioscience's main balance sheet or income statement drivers, such as Other Operating Expenses of 101.1 M, Total Operating Expenses of 98.2 M or Interest Expense of 224.8 K, as well as many indicators such as Price To Sales Ratio of 2.12, Dividend Yield of 0.0164 or PTB Ratio of 0.54. Aadi financial statements analysis is a perfect complement when working with Aadi Bioscience Valuation or Volatility modules.
  
Check out the analysis of Aadi Bioscience Correlation against competitors.
For more detail on how to invest in Aadi Stock please use our How to Invest in Aadi Bioscience guide.

Latest Aadi Bioscience's Liabilities And Stockholders Equity Growth Pattern

Below is the plot of the Liabilities And Stockholders Equity of Aadi Bioscience over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Aadi Bioscience's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aadi Bioscience's overall financial position and show how it may be relating to other accounts over time.
Liabilities And Stockholders Equity10 Years Trend
Slightly volatile
   Liabilities And Stockholders Equity   
       Timeline  

Aadi Liabilities And Stockholders Equity Regression Statistics

Arithmetic Mean51,070,185
Geometric Mean2,211,298
Coefficient Of Variation131.53
Mean Deviation56,318,229
Median18,825,000
Standard Deviation67,173,382
Sample Variance4512.3T
Range184.2M
R-Value0.83
Mean Square Error1481.7T
R-Squared0.70
Significance0.0001
Slope12,522,780
Total Sum of Squares63171.7T

Aadi Liabilities And Stockholders Equity History

2024139 M
2023132.4 M
2022184.2 M
2021157.9 M
202018.8 M
201939.9 M
201864.1 M

About Aadi Bioscience Financial Statements

Investors use fundamental indicators, such as Aadi Bioscience's Liabilities And Stockholders Equity, to determine how well the company is positioned to perform in the future. Although Aadi Bioscience's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Liabilities And Stockholders Equity132.4 M139 M

Currently Active Assets on Macroaxis

When determining whether Aadi Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aadi Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aadi Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aadi Bioscience Stock:
Check out the analysis of Aadi Bioscience Correlation against competitors.
For more detail on how to invest in Aadi Stock please use our How to Invest in Aadi Bioscience guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aadi Bioscience. If investors know Aadi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aadi Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.28)
Revenue Per Share
0.929
Quarterly Revenue Growth
0.21
Return On Assets
(0.35)
Return On Equity
(0.66)
The market value of Aadi Bioscience is measured differently than its book value, which is the value of Aadi that is recorded on the company's balance sheet. Investors also form their own opinion of Aadi Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Aadi Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aadi Bioscience's market value can be influenced by many factors that don't directly affect Aadi Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aadi Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aadi Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aadi Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.